| Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. | |
| | |
MedLine Citation:
|
PMID: 20845506 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To analyze the efficacy and safety of a combination therapy of pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV) in older Japanese patients (65 years or older) infected with hepatitis C virus (HCV). METHODS: This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk. RESULTS: At 24 wk after the end of combination therapy, the overall sustained virological response (SVR) for genotypes 1 and 2 were 40.7% and 79.6%, respectively. The SVR rate decreased significantly with age in each genotype, and was markedly reduced in genotype 1 (P < 0.001). Moreover, the SVR was significantly higher in patients with genotype 1 who were less than 65 years (47.3% of 685) than in those 65 years or older (22.9% of 253) (P < 0.001) and was higher in patients with genotype 2 who were less than 65 years (82.9% of 252) than in those 65 years or older (65.6% of 61) (P = 0.004). When patients received a dosage at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target dosage of RBV, the SVR rate significantly increased to 66.5% in patients less than 65 years and to 45.2% in those 65 years or older (P < 0.001). Adverse effects resulted in treatment discontinuation more often in patients with genotype 1 (14.4%) than in patients with genotype 2 (7.3%), especially by patients 65 years or older (24.1%). CONCLUSION: PEG-IFN α-2b plus RBV treatment was effective in chronic hepatitis C patients 65 years or older who completed treatment with at least the minimum acceptable treatment dosage. |
| | |
Authors:
|
Mosaburo Kainuma; Norihiro Furusyo; Eiji Kajiwara; Kazuhiro Takahashi; Hideyuki Nomura; Yuichi Tanabe; Takeaki Satoh; Toshihiro Maruyama; Makoto Nakamuta; Kazuhiro Kotoh; Koichi Azuma; Junya Shimono; Shinji Shimoda; Jun Hayashi; |
Related Documents
:
|
12942406 - Duration of highly active antiretroviral therapy regimens. 9879606 - Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis c... 16082736 - International, multicenter, randomized, controlled study comparing dynamically individu... 15865226 - Lamivudine treatment in hbeag-negative chronic hepatitis b patients with low level vira... 15519016 - Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchroni... 16881426 - Comparison of efficacy of 1% silver sulfadiazine and acticoat for treatment of partial-... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study |
Journal Detail:
|
Title: World journal of gastroenterology : WJG Volume: 16 ISSN: 1007-9327 ISO Abbreviation: World J. Gastroenterol. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-16 Completed Date: 2011-01-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883448 Medline TA: World J Gastroenterol Country: China |
Other Details:
|
Languages: eng Pagination: 4400-9 Citation Subset: IM |
Affiliation:
|
Department of General Internal Medicine, Kyushu University Hospital, Maidashi, Higashi-Ku, Fukuoka 812-8582, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antiviral Agents / therapeutic use* Drug Therapy, Combination Female Genotype Hepacivirus / genetics Hepatitis C, Chronic / drug therapy* Humans Interferon Alfa-2b / therapeutic use* Liver / pathology, virology Male Middle Aged Polyethylene Glycols / therapeutic use* Ribavirin / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Polyethylene Glycols; 0/peginterferon alfa-2b; 36791-04-5/Ribavirin; 99210-65-8/Interferon Alfa-2b |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic ...
Next Document: Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.